Alabama Holds Hearing on Aligning State Marijuana Schedule With Federal Move

ADPH Hearing Follows Federal Schedule III Reclassification

Alabama regulators convened a public hearing July 22 to weigh whether the state should mirror the Trump administration's federal rescheduling of marijuana from Schedule I to Schedule III. The Alabama Department of Public Health initiated the proceeding after the Drug Enforcement Administration finalized the reclassification earlier this year, a move that recognized marijuana's accepted medical use and lower abuse potential compared to Schedule I substances.

Conservative activists testified against state-level alignment. The hearing drew formal objections. No timeline for a final ADPH decision has been announced.

Conservative Groups Warn of Public-Health Messaging Risks

Opponents argued that rescheduling marijuana to Schedule III would communicate to Alabama residents that cannabis presents a low risk and has accepted medical use. One activist testified that the federal reclassification "sends a powerful message to the public that this drug has an accepted medical use, and presents a relatively low risk."

The objection centers on concern that state-level alignment would undermine anti-drug messaging in a state without adult-use legalization. Alabama currently permits medical marijuana through a tightly controlled program enacted in 2021, but recreational cannabis remains illegal under state law.

State-Federal Scheduling Alignment Remains Discretionary

Alabama isn't required to reschedule marijuana at the state level simply because the federal government did. States retain independent authority over their controlled-substance schedules. Several conservative-leaning states have signaled they may not follow the federal lead on cannabis reclassification.

Key points on state-federal scheduling dynamics:

• Federal Schedule III status doesn't override state criminal prohibitions or force state rescheduling.
• States may maintain stricter scheduling classifications than the federal government.
• Alabama's medical marijuana program operates under separate statutory authority, not controlled-substance scheduling rules.
• Rescheduling at the state level wouldn't legalize recreational use or expand the existing medical program.

Alabama's Medical Program Operates Under Narrow Framework

Alabama's 2021 medical marijuana law established a closed-loop system with restrictive qualifying conditions and no home cultivation. The program, administered by the Alabama Medical Cannabis Commission, permits dispensing for conditions including cancer-related cachexia, chronic pain, PTSD, and terminal illness. Fewer than 10 dispensaries have opened statewide as of mid-2026.

State-level rescheduling wouldn't alter the medical program's structure or expand patient access. The hearing focused solely on whether Alabama's controlled-substance schedule should align with federal classification for regulatory consistency.

What Happens Next Depends on ADPH's Administrative Process

The July 22 hearing represents the public-comment phase of Alabama's rescheduling review, but no decision is imminent. ADPH must evaluate testimony, review the federal reclassification rationale, and determine whether state alignment serves Alabama's public-health interests. The agency hasn't announced a timeline for a final rule.

For full background on this story, see the CannIntel topic hub on Alabama marijuana rescheduling. Enforcement in conservative states without adult-use programs remains unsettled. Expect wide variance in how states respond to the federal Schedule III move.